Passage Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
Passage Bio, Inc. filed this Current Report on Form 8-K on April 14, 2020, reporting material agreements entered into on or around April 10, 2020, and a manufacturing agreement dated April 13, 2020. The company develops gene therapy product candidates and is an emerging growth company.
Key Financial and Operating Metrics
- New headquarters lease: Approximately 37,000 square feet at 2005 Market Street, Philadelphia, with an expected commencement date of January 1, 2021 and expiration date of November 1, 2031.
- Lease payments: Aggregate estimated rent over the initial term is approximately $20.4 million.
- Security deposit: $34,046.84.
- Tenant improvement allowance: Up to approximately $2.8 million.
- Lease extension: The company may extend the new lease for up to two additional five-year terms.
- Existing office lease: The lease for approximately 8,887 square feet at 2001 Market Street will terminate five business days after the new lease commences, provided the company is not in breach.
- Manufacturing commitment: The Catalent agreement requires minimum annual purchases of drug-product batches, subject to inflation adjustments. The filing text does not provide the minimum purchase amounts, total commitment, or expected manufacturing costs.
Material Changes, Outlook, and Risks
- The new headquarters lease represents a long-term real-estate commitment and is expected to replace the company’s existing office lease.
- The five-year Catalent manufacturing and supply agreement, with an optional five-year extension, is intended to secure clinical-scale manufacturing capacity for the company’s gene therapy candidates.
- The company may terminate the manufacturing agreement for convenience or specified reasons, but termination under certain circumstances would require an early termination fee.
- Either party may terminate the manufacturing agreement following an uncured material breach, bankruptcy or insolvency, or FDA or U.S. government suspension or debarment of the other party.
- The filing does not provide revenue, net income, cash flow, cash balance, debt, liquidity, or margin information.
Important Facts for Investors to Verify
- Review the full One Commerce Lease for rent schedules, operating expenses, renewal terms, construction obligations, and termination provisions.
- Confirm the timing and accounting treatment of the $20.4 million lease commitment and the $2.8 million tenant improvement allowance.
- Review the Lease Amendment and confirm that the prior lease terminates as expected after the new premises commence.
- Review the full Catalent agreement for minimum annual purchase obligations, pricing, capacity commitments, early termination fees, and delivery or performance remedies.
- Assess whether these long-term commitments are supported by the company’s available cash and financing plans; this filing does not provide that information.